PSTV Stock | | | USD 1.35 0.04 3.05% |
Plus Therapeutics financial indicator trend analysis is much more than just breaking down Plus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Plus Therapeutics is a good investment. Please check the relationship between Plus Therapeutics Total Operating Expenses and its Operating Income accounts. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
For more information on how to buy Plus Stock please use our
How to Invest in Plus Therapeutics guide.
Total Operating Expenses vs Operating Income
Total Operating Expenses vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Plus Therapeutics Total Operating Expenses account and
Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Plus Therapeutics' Total Operating Expenses and Operating Income is -0.91. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Plus Therapeutics, assuming nothing else is changed. The correlation between historical values of Plus Therapeutics' Total Operating Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Plus Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Total Operating Expenses i.e., Plus Therapeutics' Total Operating Expenses and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.91 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Operating Income
Operating Income is the amount of profit realized from Plus Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Plus Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Plus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
For more information on how to buy Plus Stock please use our
How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics'
Selling General Administrative is fairly stable compared to the past year.
Issuance Of Capital Stock is likely to climb to about 9.1
M in 2024, whereas
Enterprise Value Over EBITDA is likely to drop
(0.09) in 2024.
Plus Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Plus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Plus Therapeutics fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to
measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.